Business
Admission to AIM & First Day of Dealings
Admission to AIM & First Day of Dealings.
About this update from Diaceutics Plc
[{"type":"text","content":"\n \nRNS Number : 4937T Diaceutics PLC 21 March 2019 \n\n \nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.\nDiaceutics PLC\n(\"Diaceutics\" or the \"Company\")\n \nAdmission to trading on AIM and First Day of Dealings\n \nDiaceutics PLC, a data analytics and implementation services company which services the global pharmaceutical industry, announces the admission of its entire issued ordinary share capital, which comprises 69,583,077 ordinary shares (\"Ordinary Shares\") to trading on the AIM market of the London Stock Exchange (\"Admission\") today, 21 March 2019. Dealings in the Ordinary Shares will commence at 8:00 a.m. under the ticker \"DXRX\" and ISIN GB00BJQTGV64.\n \nThe Company's Admission Document is available from www.diaceutics.com \n \nThe Company has successfully raised £17 million gross (before expenses) through a placing of 22,368,427 new Ordinary Shares through its nominated adviser and broker, Cenkos Securities plc. In addition, 4,934,205 existing Ordinary Shares have been placed on behalf of existing shareholders. \n \nTransaction highlights \n \n· £17 million raised by the conditional placing of 22,368,427 new Ordinary Shares at a placing price of 76p\n· The new Ordinary Shares represent 32.15 per cent. of the enlarged share capital on Admission\n· Enlarged share capital on Admission of 69,583,077 Ordinary Shares\n· £52.9 million market capitalisation on Admission at the placing price\n· Cenkos Securities plc is Nominated Adviser and Broker\n \nPeter Keeling, CEO of Diaceutics PLC, said: \"We are very pleased with the level of interest generated from new institutional investors in support of our admission to trading on AIM. The move to AIM and the additional funding will allow us to continue our growth trajectory by developing our product and services offering which is focused on better testing and better treatment in the global pharmaceutical industry. The name Diaceutics reflects our activities at the intersection between dia...